Fulcrum Therapeutics (NASDAQ: FULC) net income
Fulcrum Therapeutics reported a net loss of $74.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $9.7m. Earnings per share were −$1.18.
Fulcrum Therapeutics's best year of the last 8 was fiscal 2024. It reported a loss in 8 of those 8 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$74.9m | — | — | −$1.18 |
| 2024 | −$9.7m | — | −12.2% | −$0.16 |
| 2023 | −$97.3m | — | −3,470.1% | −$1.59 |
| 2022 | −$109.9m | — | −1,732.4% | −$2.44 |
| 2021 | −$80.8m | — | −421.9% | −$2.29 |
| 2020 | −$70.8m | — | −802.7% | −$2.79 |
| 2019 | −$82.7m | — | — | — |
| 2018 | −$32.6m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Fulcrum Therapeutics net income compared with its sector
By net income for its latest fiscal year, Fulcrum Therapeutics ranks 304th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 302nd | Foghorn Therapeutics | −$74.3m | −240.3% |
| 303rd | MacroGenics | −$74.6m | −49.9% |
| 304th | Fulcrum Therapeutics | −$74.9m | — |
| 305th | Butterfly Network | −$77.1m | −79.0% |
| 306th | Rezolute | −$77.6m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Fulcrum Therapeutics
- How much did Fulcrum Therapeutics earn in fiscal 2025?
- Fulcrum Therapeutics reported a net loss of $74.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $9.7m.
- What are the earnings per share of Fulcrum Therapeutics?
- They were −$1.18 in fiscal 2025, compared with −$0.16 in fiscal 2024.
- Where does Fulcrum Therapeutics rank in its sector by net income?
- It ranks 304th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Fulcrum Therapeutics come from?
- From the annual report (Form 10-K) that Fulcrum Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Fulcrum Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Fulcrum Therapeutics: the Fulcrum Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.